VEGFA and renal cell carcinoma: The VEGF-driven mechanisms involved in RCC oncogenesis, combined with the evidence that anti-angiogenesis therapy has an immunomodulatory effect, provided a basis for combining ICB with angiogenesis inhibitors in the first-line setting [28].